 Sarepta Therapeutics Inc said it would be delayed at least six months in seeking approval for its lead drug candidate after the US Food and Drug Administration demanded additional information because of concerns about the companys clinicaltrial data In Nasdaq trading Monday the companys shares sank  on news of the delay to   Sarepta
  